Recruiting studies: Bos

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.
Phase 2 · 1 location(s) · Steven Hays, MD · NCT06018766 Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation
Phase 2 · 3 location(s) · University Hospital, Basel, Switzerland · NCT03805477 ASXL-Related Disorders Natural History Study
Phase N/A · 1 location(s) · University of California, Los Angeles · NCT03303716 Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung
Phase 3 · 20 location(s) · Renovion, Inc. · NCT05654922 Forced Oscillatory Technique for Bronchiolitis Obliterans Syndrome After Allogeneic Bone Marrow Transplantation
NA · 1 location(s) · Hadassah Medical Organization · NCT07730931 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168 Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
Phase N/A · 3 location(s) · Brian Keller · NCT07434869 Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respira
NA · 1 location(s) · Commissariat A L'energie Atomique · NCT05724745

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.